Valued at USD 12.92 billion in 2024, the Castrate-Resistant Prostate Cancer Market is projected to reach USD 14.04 billion in 2025 and USD 29.79 billion by 2034, growing at a CAGR of 8.7% during the forecast period 2025–2034. Expansion reflects more diagnoses of advanced prostate cancer, improved awareness and early detection, and new developments in treatment that help patients live longer. North America held the largest share in 2024.

Disease Burden and Treatment Demand

Castrate-resistant prostate cancer (CRPC) keeps growing despite treatments that lower testosterone. It often spreads to bones or lymph nodes and is identified by rising PSA levels despite low testosterone. The American Cancer Society predicted about 299,010 new prostate cancer cases in the United States in 2024, with around 35,250 deaths. As more patients transition to CRPC, demand for effective treatments increases. Enhanced awareness campaigns and better diagnostic tools enable earlier identification of progression, while increased oncology research funding and ongoing clinical trials boost innovation.

Improved awareness and early detection have increased demand for treatment, and the aging population further contributes to growth. Treatment options include advanced hormone therapies, chemotherapy, immunotherapy, and bone-targeting agents to manage symptoms and improve survival.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/castrate-resistant-prostate-cancer-market

Therapy Segmentation: Hormonal Treatment Leads

By therapy, the market is divided into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. Hormonal therapy held the largest share in 2024 owing to its effectiveness in managing disease progression and extending survival. Androgen receptor inhibitors such as enzalutamide and androgen biosynthesis inhibitors such as abiraterone acetate have become standard treatments because they target cancer cells more precisely and delay progression.

Robust clinical evidence, regulatory approvals, and expanding patient access underpin adoption. The report also notes a preference for hormonal approaches over chemotherapy in early-stage CRPC, which solidified the segment's position as the largest contributor. Sanofi's Jevtana (cabazitaxel) has emerged as a significant advancement in prostate cancer management.

Regional Analysis

North America accounted for the largest share in 2024 due to advanced healthcare infrastructure and high prostate cancer prevalence. Mayo Clinic was the first medical center to receive FDA approval to prepare and administer the choline C-11 PET scan, which detects recurrence earlier than traditional imaging. According to the National Cancer Institute, around 3.4 million men in the US were diagnosed with prostate cancer in 2021.

Favorable reimbursement policies, awareness of prostate cancer management, early adoption of advanced modalities, strong R&D investment, and regulatory support reinforce regional leadership. The US held the largest country share thanks to leading pharmaceutical companies and ongoing drug development, including androgen receptor inhibitors. Asia Pacific is expected to record the highest CAGR on rising cancer incidence among a growing elderly population and changing lifestyle factors.

Key Players in the Castrate-Resistant Prostate Cancer Market

Key players include Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc.; and Dendreon Corporation.

Major pharmaceutical companies such as Johnson & Johnson, Astellas Pharma, Bayer, and Pfizer dominate with leading treatments, including Zytiga (abiraterone acetate), Xtandi (enzalutamide), and Janssen's Erleada. Strong brands, R&D investment, and extensive clinical trial portfolios support their positions, while biotechnology firms are entering with a focus on targeted therapies and novel androgen receptor antagonists, and partnerships, collaborations, and acquisitions continue to shape competition. Company profiles in the report cover overview, financial performance, product benchmarking, and recent developments.

Recent Developments and Outlook

In May 2025, the FDA's Oncologic Drugs Advisory Committee unanimously voted against approving the combination of talazoparib and enzalutamide for non-HRR-mutant metastatic castration-resistant prostate cancer, citing results from the phase 3 TALAPRO-2 trial. In June 2024, AstraZeneca completed its acquisition of Fusion Pharmaceuticals, adding candidate FPI-2265 for metastatic disease.

Fast-track designations and regulatory approvals are accelerating novel drug entry, while focus on combination therapies and personalized medicine is expected to intensify competition.

More Trending Latest Reports By Polaris Market Research:

jewelry-market

telehealth-market

hot-sauce-market

long-term-care-market

corrugated-plastic-sheets-a-sustainable-solution-for-modern-industry

cleanroom-technology-market

industrial-pumps-market

rising-demand-driving-additive-manufacturing

linseed-oil-market